GLAXO GlaxoSmithKline Pharmaceuticals Q3 FY25 results (Oct–Dec 2024) and concall
Glaxosmi. Pharma reported a strong Q3 FY25, with revenue growing 18% and EBITDA up 33%, driven by double-digit growth across all segments including general medicines, specialty, and vaccines. The company maintained a healthy EBITDA margin of 30.7% and remains debt-free with robust cash flow. Management highlighted strategic focus on new product launches in oncology and continued investment in building the adult vaccination ecosystem, while acknowledging the need for sustained effort in a commoditizing market.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 1,011 | 949 |
| EBITDA | 322 | 292 |
| Net profit | 252 | 230 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
